Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design

博士 === 國立臺北科技大學 === 工程科技研究所 === 100 === Histamine, a biogenic amine, plays many important pathophysiological roles in human tissues such as mediator in allergic responses, a regulator of gastric acid secretion, a messenger in bronchial asthma, and a neurotransmitter in the central nervous system. Th...

Full description

Bibliographic Details
Main Authors: Pavadai Elumalai, P.Elumalai
Other Authors: 劉宣良
Format: Others
Language:en_US
Published: 2012
Online Access:http://ndltd.ncl.edu.tw/handle/ex8g23
id ndltd-TW-100TIT05028042
record_format oai_dc
spelling ndltd-TW-100TIT050280422019-05-15T20:51:54Z http://ndltd.ncl.edu.tw/handle/ex8g23 Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design 以受質與結構為基礎的藥物設計來開發新穎的組織胺N-甲基轉移酶抑制劑 Pavadai Elumalai P.Elumalai 博士 國立臺北科技大學 工程科技研究所 100 Histamine, a biogenic amine, plays many important pathophysiological roles in human tissues such as mediator in allergic responses, a regulator of gastric acid secretion, a messenger in bronchial asthma, and a neurotransmitter in the central nervous system. The histamine is inactivated by histamine-metabolizing major enzyme histamine N-methyltransferase (EC 2.1.1.8; HNMT) in various tissues for example bronchus, kidney and the central nervous system. Importantly, it has been shown that HNMT is the only pathway for termination of the neurotransmitter action of histamine in the brain. Recently, the inhibition of HNMT has been demonstrated to play therapeutic roles in the treatment of neurodegenerative disease, memory and learning deficits and attention-deficit hyperactivity disorder. Thus, to better understand the essential chemical features for HNMT inhibition and discover novel HNMT inhibitors, common feature, ligand-based and structure-based pharmacophore models were, in this study, developed based on the most active inhibitors, structurally divers inhibitors and the highest resolution crystal structure of HNMT using Hip-Hop, HypoGen and Ludi algorithms of Discovery Studio 2.5 software, respectively. The best models were selected and the goodness-of-hit validation scores of three models showed more than 0.7, indicating that the pharmacophore models are efficient to identify novel hits using virtual screening techniques. The pharmacophore models were then employed as 3D-search query for virtual screening to retrieve potential hits from NCI, Chembridge and Maybridge databases. Subsequently, the hit compounds were subjected to molecular docking studies with the crystal structure of human HNMT. Finally, total of 20 hits were suggested as potential leads, which exhibited good estimated activities, favorable binding interactions, high pharmacophore fit values and high consensus scores. The obtained novel chemotype from these studies could facilitate to discover new scaffold in the development of novel HNMT inhibitors. 劉宣良 2012 學位論文 ; thesis 162 en_US
collection NDLTD
language en_US
format Others
sources NDLTD
description 博士 === 國立臺北科技大學 === 工程科技研究所 === 100 === Histamine, a biogenic amine, plays many important pathophysiological roles in human tissues such as mediator in allergic responses, a regulator of gastric acid secretion, a messenger in bronchial asthma, and a neurotransmitter in the central nervous system. The histamine is inactivated by histamine-metabolizing major enzyme histamine N-methyltransferase (EC 2.1.1.8; HNMT) in various tissues for example bronchus, kidney and the central nervous system. Importantly, it has been shown that HNMT is the only pathway for termination of the neurotransmitter action of histamine in the brain. Recently, the inhibition of HNMT has been demonstrated to play therapeutic roles in the treatment of neurodegenerative disease, memory and learning deficits and attention-deficit hyperactivity disorder. Thus, to better understand the essential chemical features for HNMT inhibition and discover novel HNMT inhibitors, common feature, ligand-based and structure-based pharmacophore models were, in this study, developed based on the most active inhibitors, structurally divers inhibitors and the highest resolution crystal structure of HNMT using Hip-Hop, HypoGen and Ludi algorithms of Discovery Studio 2.5 software, respectively. The best models were selected and the goodness-of-hit validation scores of three models showed more than 0.7, indicating that the pharmacophore models are efficient to identify novel hits using virtual screening techniques. The pharmacophore models were then employed as 3D-search query for virtual screening to retrieve potential hits from NCI, Chembridge and Maybridge databases. Subsequently, the hit compounds were subjected to molecular docking studies with the crystal structure of human HNMT. Finally, total of 20 hits were suggested as potential leads, which exhibited good estimated activities, favorable binding interactions, high pharmacophore fit values and high consensus scores. The obtained novel chemotype from these studies could facilitate to discover new scaffold in the development of novel HNMT inhibitors.
author2 劉宣良
author_facet 劉宣良
Pavadai Elumalai
P.Elumalai
author Pavadai Elumalai
P.Elumalai
spellingShingle Pavadai Elumalai
P.Elumalai
Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design
author_sort Pavadai Elumalai
title Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design
title_short Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design
title_full Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design
title_fullStr Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design
title_full_unstemmed Discovery of Novel Human HNMT Inhibitors through Ligand and Structure-Based Drug Design
title_sort discovery of novel human hnmt inhibitors through ligand and structure-based drug design
publishDate 2012
url http://ndltd.ncl.edu.tw/handle/ex8g23
work_keys_str_mv AT pavadaielumalai discoveryofnovelhumanhnmtinhibitorsthroughligandandstructurebaseddrugdesign
AT pelumalai discoveryofnovelhumanhnmtinhibitorsthroughligandandstructurebaseddrugdesign
AT pavadaielumalai yǐshòuzhìyǔjiégòuwèijīchǔdeyàowùshèjìláikāifāxīnyǐngdezǔzhīànnjiǎjīzhuǎnyíméiyìzhìjì
AT pelumalai yǐshòuzhìyǔjiégòuwèijīchǔdeyàowùshèjìláikāifāxīnyǐngdezǔzhīànnjiǎjīzhuǎnyíméiyìzhìjì
_version_ 1719106038375907328